Efficacy and Safety of Dapagliflozin, Added to Therapy of Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin

Completed · Phase 3 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

This study is being carried out to see if Dapagliflozin in addition to insulin is effective and safe in treating patients with type 2 diabetes when compared to placebo (identical looking inactive treatment) in addition to insulin

Key facts

Study ID

NCT00673231

Run by

AstraZeneca

People needed

1240

Starts

2008-04-01

Expected to finish

2011-01-01

Last updated by the study team

2013-10-29

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Type 2 Diabetes
• Patients with HbA1c ≥7.5% and ≤10.5% and who are on a stable insulin regimen of at least 30 IU of injectable insulin per day either without any other oral antidiabetic drug or with a stable dose of oral antidiabetic drugs

You may not qualify if…

• Type 1 Diabetes
• Treatment with more than two additional oral antidiabetic drugs
• Moderate and severe renal (kidney) failure or dysfunction

Where it is running

• Research Site — Greenbrae, California, United States
• Research Site — Roswell, Georgia, United States
• Research Site — Chicago, Illinois, United States
• Research Site — Springfield, Illinois, United States
• Research Site — Indianapolis, Indiana, United States
• Research Site — Omaha, Nebraska, United States
• Research Site — Philadelphia, Pennsylvania, United States
• Research Site — Corpus Christi, Texas, United States
• Research Site — Dallas, Texas, United States
• Research Site — Norfolk, Virginia, United States
• Research Site — Richmond, Virginia, United States
• Research Site — Tacoma, Washington, United States
• Research Site — Salzburg, Austria
• Research Site — Vienna, Austria
• Research Site — Pleven, Bulgaria
• Research Site — Rousse, Bulgaria
• Research Site — Sofia, Bulgaria
• Research Site — Varna, Bulgaria
• Research Site — Calgary, Alberta, Canada
• Research Site — Kelowna, British Columbia, Canada
• Research Site — Langley, British Columbia, Canada
• Research Site — Winnipeg, Manitoba, Canada
• Research Site — Moncton, New Brunswick, Canada
• Research Site — Mount Pearl, Newfoundland and Labrador, Canada
• Research Site — Fresno, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.